About HIPRA
HIPRA is a company based in Amer (Spain) founded in 1996. The company has 22 employees as of April 06, 2024. HIPRA has completed 1 acquisition, including GoodGut. HIPRA operates in a competitive market with competitors including Pardes Biosciences, ExeVir Bio, Inimmune, Vaxxinity and Alchemab, among others.
- Headquarter Amer, Spain
- Employees 22 as on 06 Apr, 2024
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Hipra India Private Limited
- Date of Incorporation 14 Feb, 2012
- Jurisdiction Pune, Maharashtra, India
-
Annual Revenue
$2.03 M (USD)27.25as on Mar 31, 2023
-
Net Profit
-$576.99 K (USD)-24.72as on Mar 31, 2023
-
EBITDA
-$575.87 K (USD)-24.83as on Mar 31, 2023
-
Latest Funding Round
$2.35 M (USD), Grant
Dec 01, 2021
- Investors
-
Employee Count
22
as on Apr 06, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of HIPRA
Unlock access to complete
Software Development Team
45 people
R Team
20 people
Sales and Marketing
18 people
Product Management Team
11 people
Leadership Team
10 people
Regulatory Team
8 people
Data Analysis and Operations Team
3 people
Key Team
2 people
Unlock access to complete
Funding Insights of HIPRA
Investors in HIPRA
HIPRA has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for HIPRA
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by HIPRA
HIPRA has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include GoodGut.
Investment portfolio details for HIPRA
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Diagnosis and treatment of digestive diseases based on intestinal microbiota analysis
|
Locked | Locked | 2014 | Locked |
Complete acquisition details for HIPRA
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - HIPRA
Detailed financials for HIPRA
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Hipra Comparisons
Peer comparison for HIPRA
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of HIPRA
HIPRA operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Pardes Biosciences, ExeVir Bio, Inimmune, Vaxxinity and Alchemab, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for pandemic diseases including SARS-CoV-2 are developed.
|
|
| Locked | Locked | Locked |
Provider of antibody-based therapies to monitor viral infections
|
|
| Locked | Locked | Locked |
Integrated clinical developmental services to treat food allergy, allergic rhinitis, and auto-immune disorders
|
|
| Locked | Locked | Locked |
Vaccines for neurological disorders and infectious diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of antibody based therapeutics to treat cancers, neurodegenerative conditions and infectious diseases
|
|
| Locked | Locked | Locked |
mRNA-based therapeutics for cancer and COVID-19 are developed.
|
Detailed competitors of HIPRA
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Hipra
Complete news archive for HIPRA
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about HIPRA
HIPRA was founded in 1996 and raised its 1st funding round 25 years after it was founded.
HIPRA is headquartered in Amer, Spain. It is registered at Amer, Cataluna, Spain.
As of Apr 06, 2024, the latest employee count at HIPRA is 22.
Annual revenue of HIPRA is $2.03M as on Mar 31, 2023.
HIPRA was established in 1996 in Amer, Spain, within the animal health sector. Vaccines are produced for conditions such as viral nervous necrosis, bursal disease, and respiratory syncytial virus. Diagnostic kits are offered for detection and quantification of pathogens including mycoplasma hyopneumoniae and Leishmania donovani infantum. Operations focus on veterinary applications, with services extending to various animal species across international markets.
HIPRA's top competitors include Ethris, ExeVir Bio and Alchemab.
HIPRA has made 1 acquisition, including GoodGut.
HIPRA has 1 investor. Key investors include European Union.